Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Edmond Dik Lung Ma"'
Autor:
Wei Cui, Zhi-Xiu Lin, Yifan Han, Shengquan Hu, Zaijun Zhang, Huan Zhang, Fei Sa, Tony Chunglit Choi, Sai Li, Daping Xu, Simon My Lee, Edmond Dik Lung Ma, Zhong Zuo, Renwen Han, Jianhui Rong, Shinghung Mak, Wenming Li, Shuai Yuan
Publikováno v:
British Journal of Pharmacology. 168:1201-1214
Background and Purpose SU4312, a potent and selective inhibitor of VEGF receptor-2 (VEGFR-2), has been designed to treat cancer. Recent studies have suggested that SU4312 can also be useful in treating neurodegenerative disorders. In this study, we a
Autor:
Tony Chunglit Choi, Yuqiang Wang, Edmond Dik Lung Ma, Baojian Guo, Shinghung Mak, Yifan Han, Fangcheng Luo, Guozhen Cui, Chengyou Zheng, Shengquan Hu, Simon Ming-Yuen Lee, Hongyu Wang, Xifei Yang, Haitao Li, Wei Cui, Zaijun Zhang
Publikováno v:
Neuropharmacology. 126
We have previously demonstrated the unexpected neuroprotection of the anti-cancer agent SU4312 in cellular models associated with Parkinson's disease (PD). However, the precise mechanisms underlying its neuroprotection are still unknown, and the effe
Autor:
Yuan Ping Pang, Tony Chunglit Choi, Yifan Han, Shujun Xu, Qinwen Wang, Edmond Dik Lung Ma, Victor Pui-Yan Ma, Hongjun Fu, Shengquan Hu, Liang Tao, Juwei Hu, Wenhua Zhou, Roger Anwyl, Michael J. Rowan, Yong Yang, Wei Cui, Lan Chang, Shinghung Mak, Qin Wang
Publikováno v:
Scientific Reports
β-amyloid (Aβ) oligomers have been closely implicated in the pathogenesis of Alzheimer’s disease (AD). We found, for the first time, that bis(heptyl)-cognitin, a novel dimeric acetylcholinesterase (AChE) inhibitor derived from tacrine, prevented
Autor:
Wei, Cui, Zaijun, Zhang, Wenming, Li, Shengquan, Hu, Shinghung, Mak, Huan, Zhang, Renwen, Han, Shuai, Yuan, Sai, Li, Fei, Sa, Daping, Xu, Zhixiu, Lin, Zhong, Zuo, Jianhui, Rong, Edmond Dik-Lung, Ma, Tony Chunglit, Choi, Simon My, Lee, Yifan, Han
Publikováno v:
British journal of pharmacology. 168(5)
SU4312, a potent and selective inhibitor of VEGF receptor-2 (VEGFR-2), has been designed to treat cancer. Recent studies have suggested that SU4312 can also be useful in treating neurodegenerative disorders. In this study, we assessed neuroprotection